ArticleESC heart failure2020
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty.
Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies.Journal of the American Heart Association · 2022Pooled it
- Limited predictive value of traditional comorbidities for readmission in acute decompensated heart failure.PloS one · 2025Article
- Decline in oral function contributes to decreased activities of daily living at discharge in elderly patients with heart failure.PloS one · 2025Article
- Impact of sodium-glucose cotransporter-2 inhibitor use on peak VOFrontiers in cardiovascular medicine · 2024Article
- Effects of sacubitril/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction.Frontiers in cardiovascular medicine · 2024Article
- Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.European journal of clinical pharmacology · 2023Article
- An evidence-based debate on epigenetics and immunosenescence in COVID-19.Current research in immunology · 2023Review
- Frailty and solid-organ transplant candidates: a scoping review.BMC geriatrics · 2022Article
- Moving the Field Forward: Untangling the Impact of Frailty on Patients With Advanced Heart Failure and on Prognosticating Outcomes.Journal of cardiac failure · 2022Article
- Haemodynamic effects of sacubitril/valsartan in advanced heart failure.ESC heart failure · 2022Observational
- Differences According to Age in the Diagnostic Performance of Cardiac Biomarkers to Predict Frailty in Patients with Acute Heart Failure.Biomolecules · 2022Article
- Clinical Perspectives on Cardiac Rehabilitation After Heart Failure in Elderly Patients with Frailty: A Narrative Review.Therapeutics and clinical risk management · 2022Review
- Prevalence and prognostic value of the coexistence of anaemia and frailty in older patients with heart failure.ESC heart failure · 2021Observational
- Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction.Frontiers in cardiovascular medicine · 2021Article
- Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.Vascular health and risk management · 2021Review
- Predicting non-elective hospital readmission or death using a composite assessment of cognitive and physical frailty in elderly inpatients with cardiovascular disease.BMC geriatrics · 2020Article
- Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty.ESC heart failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study was to investigate prospectively the effect of sacubitril/valsartan in advanced heart failure (HF) patients in waiting list for heart transplantation (HT) and the effect on physical frailty (PF). METHODS AND
resultsWe treated 37 consecutive patients with advanced HF with sacubitril/valsartan. Patients were followed up until HT, device implant, or last follow-up visit after 2 years of follow-up. At baseline, mean New York Heart Association (NYHA) class was 3.1 ± 0.4, with 64.9% in NYHA III and 35.1% NYHA IIIB. Left ventricular ejection fraction was 23.5 ± 5.8%, VO
conclusionsOur study showed a rapid improvement in PF in HT waiting list patients treated with sacubitril/valsartan. The improvement in all PF domains was paralleled by VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.